74.JPG)
The Lyophilization Services for Biopharmaceuticals Market Size is valued at 894.70 Million in 2023 and is predicted to reach 2024.13 Million by the year 2031 at an 11.1 % CAGR during the forecast period for 2024-2031.
Lyophilization is a method that involves freezing a substance at extremely low temperatures and then extracting liquid via sublimation, thereby transforming solid water into gaseous water. A significant advantage of this process is that the extracted water goes directly from solid to gas without passing through the liquid phase. This process is exceptional at extending a product's shelf life and storage time while preserving its three-dimensional structure and integrity. It is a modern alternative to the cryopreservation technique, which was generally used for cell and tissue preservation.
Lyophilizers freeze the material, then reduce the pressure and add heat to allow the frozen water in the material to sublimate. The lyophilized formulation has the advantage of better stability and provides easy handling, i.e. shipping and storage. To minimize detrimental effects, lyophilized products sensitive to oxidation can be stoppered and sealed within an inert atmosphere (i.e. nitrogen). This technique is useful in developing thermolabile and unstable drugs in an aqueous medium. The majority of lyophilized or freeze-dried products in the pharmaceutical industry are used for parenteral application.
Increasing investment, demand for easy drug packaging and transport, and the need for better preservation of heat-sensitive drugs will be responsible for the fast growth of the service industry. Technical advancement in lyophilization equipment and continuous research on process validation will support the development of the Lyophilization Services for Biopharmaceuticals market. In Nov 2021, Baxter Biopharma announced an approximately $100 million expansion of its sterile fill/finish manufacturing facility in Germany. This investment expands Baxter's manufacturing footprint and improves shelf life through Lyophilization. It is a long and cost-intensive process, and it requires sterile diluents for reconstitution. Lyophillization is mostly used when the product is unstable and heat-liable. The limited amount of vials processed in each process run restricts the overall production capacity. Alternatives for Lyophilization like spray drying, High cost of setup and maintenance of machines and methods, and strict regulatory guidelines will hinder the market growth to some extent.
The Asia Pacific and North America will hold the largest market share due to expansions of drug and biotechnology companies and extensive research on drug development. Companies are doing collaborations and strategic partnerships for rapid growth to achieve the production goals.
Market Segmentation
Global Lyophilization Services for Biopharmaceuticals Market is segmented into two main segments, Type of Biologic Lyophilized and Type of Primary Packaging System. The type of biologic lyophilized is again sub-segmented into four parts antibodies, cell and gene therapies in which living cells are preserved at room temperature for a prolonged period without loss of viability, vaccines and other biologics. The type of primary packaging system is divided into vials, syringes, cartridges, ampoules and others.
Competitive Landscape
Some Major Key Players In The Lyophilization Services For Biopharmaceuticals Market:
- AB BioTechnologies, Inc.
- Albany Molecular Research (AMRI)
- ATTWILL Medical Solutions
- Axcellerate Pharma LLC.
- Baxter BioPharma Solutions
- Berkshire Sterile Manufacturing, Inc.
- Biofortuna Ltd
- BioZed Engineering
- CinnaGen
- CordenPharma
- Curia
- Emergent BioSolutions
- Jubilant HollisterStier LLC
- LSNE Contract Manufacturing
- Lyophilization Technology, Inc.
- MabPlex
- Northway Biotech
- ProJect Pharmaceutics
- Samsung Biologics
- Synerlab Group
- Vetter Pharma
- WuXi Biologics
Lyophilization Services for Biopharmaceuticals Market Report Scope
|
Report Attribute |
Specifications |
|
Market Size Value In 2023 |
USD 894.70 Million |
|
Revenue Forecast In 2031 |
USD 2024.13 Million |
|
Growth Rate CAGR |
CAGR of 11.1 % from 2024 to 2031 |
|
Quantitative Units |
Representation of revenue in US$ Million and CAGR from 2024 to 2031 |
|
Historic Year |
2019 to 2023 |
|
Forecast Year |
2024-2031 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
Product, Indication |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico ;The UK; France; Italy; Spain; China; Japan; India; South Korea; South East Asia; South Korea; South East Asia |
|
Competitive Landscape |
AB BioTechnologies, Inc., Albany Molecular Research (AMRI), ATTWILL Medical Solutions, Axcellerate Pharma LLC., Baxter BioPharma Solutions, Berkshire Sterile Manufacturing, Inc., Biofortuna Ltd, BioZed Engineering, CinnaGen, CordenPharma, Curia, Emergent BioSolutions, Jubilant HollisterStier LLC, LSNE Contract Manufacturing, Lyophilization Technology, Inc., MabPlex, Northway Biotech, ProJect Pharmaceutics, Samsung Biologics, Synerlab Group, Vetter Pharma, and WuXi Biologics |
|
Customization Scope |
Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing And Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Corporate
Office :
Office No.5170, 5th Floor Marvel Fuego, Magarpatta Rd, Pune, 411028
info@insightaceanalytic.com
